← Back to Clinical Trials
Recruiting NCT06880809

NCT06880809 Bridge the Gap (BTG) - Black Youth Group

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06880809
Status Recruiting
Phase
Sponsor Children's Hospital Los Angeles
Condition Suicide Prevention
Study Type INTERVENTIONAL
Enrollment 16 participants
Start Date 2025-06-01
Primary Completion 2027-01-01

Eligibility & Interventions

Sex All sexes
Min Age 12 Years
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
Bridge the Gap (BTG) - Black Youth Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 16 participants in total. It began in 2025-06-01 with a primary completion date of 2027-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to develop and preliminarily test a culturally adapted suicide intervention specifically for black youth. The main question it aims to answer: -To evaluate the feasibility and acceptability of the group, as well as the preliminary efficacy of the group for decreasing suicidal thoughts and behaviors and increasing protective factors such as hope, positive ethnic identity, and family and peer support. Participants will be asked to attend 10-week group intervention and complete pre-treatment and post-treatment assessment measures.

Eligibility Criteria

Inclusion Criteria: * 12-17 years old * Identify as Black or African American or being of African descent * Have current suicidal ideation or suicidal ideation within the last 30 days * Have assent from the adolescent participant and consent from an individual's caregiver or guardian to participate. Exclusion Criteria: * An active psychotic disorder or current psychosis symptoms * No history of suicide attempt(s) or suicide ideation in the past 30 days * Cognitive deficits or a medical condition diagnosed from a medical provider that precludes full understanding of study materials as assessed through an inability to complete the pre-treatment CAMS SSF \& SSP * Caregivers, guardians, and/or the patient refuse to participate.

Contact & Investigator

Central Contact

Tia Tyndal, PhD

✉ ttyndal@chla.usc.edu

📞 323-361-4648

Principal Investigator

Tia Tyndal, PhD

PRINCIPAL INVESTIGATOR

Children's Hospital Los Angeles

Frequently Asked Questions

Who can join the NCT06880809 clinical trial?

This trial is open to participants of all sexes, aged 12 Years or older, up to 17 Years, studying Suicide Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06880809 currently recruiting?

Yes, NCT06880809 is actively recruiting participants. Contact the research team at ttyndal@chla.usc.edu for enrollment information.

Where is the NCT06880809 trial being conducted?

This trial is being conducted at Los Angeles, United States.

Who is sponsoring the NCT06880809 clinical trial?

NCT06880809 is sponsored by Children's Hospital Los Angeles. The principal investigator is Tia Tyndal, PhD at Children's Hospital Los Angeles. The trial plans to enroll 16 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology